These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 9465839)

  • 1. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.
    Schaedeli F; Uehlinger DE
    Clin Pharmacol Ther; 1998 Jan; 63(1):26-38. PubMed ID: 9465839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
    Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
    Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clearance of vancomycin during high-efficiency hemodialysis.
    Klansuwan N; Ratanajamit C; Kasiwong S; Wangsiripaisan A
    J Med Assoc Thai; 2006 Jul; 89(7):986-91. PubMed ID: 16881431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis.
    Ariano RE; Fine A; Sitar DS; Rexrode S; Zelenitsky SA
    Am J Kidney Dis; 2005 Oct; 46(4):681-7. PubMed ID: 16183423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
    Thomson AH; Staatz CE; Tobin CM; Gall M; Lovering AM
    J Antimicrob Chemother; 2009 May; 63(5):1050-7. PubMed ID: 19299472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
    Yang RH; Rong XZ; Hua R; Zhang T
    Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.
    Jarkowski A; Forrest A; Sweeney RP; Tan W; Segal BH; Almyroudis N; Wang ES; Wetzler M
    J Oncol Pharm Pract; 2012 Mar; 18(1):91-6. PubMed ID: 21521799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of gender and body mass on hemodialysis dose].
    Kovacić V; Sain M; Dzanko D
    Acta Med Croatica; 2003; 57(1):33-7. PubMed ID: 12876860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target quantity for twice-a-week hemodialysis: the EKR (equivalent renal urea clearance) approach.
    Manotham K; Tiranathanagul K; Praditpornsilpa K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S79-85. PubMed ID: 17044458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vancomycin dosing in hemodialysis patients].
    Castellano I; González Castillo PM; Covarsí A; Martínez Sánchez J; Suárez Santisteban MA; Gallego S; Marigliano N
    Nefrologia; 2008; 28(6):607-12. PubMed ID: 19016633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of the number of peritonitis episodes on peritoneal membrane function].
    Jovanović D; Nesić V; Dimitrijević Z
    Srp Arh Celok Lek; 1999; 127(1-2):28-31. PubMed ID: 10377837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of vancomycin in patients with severely impaired renal function.
    Gonzalez-Martin G; Acuna V; Perez C; Labarca J; Guevara A; Tagle R
    Int J Clin Pharmacol Ther; 1996 Feb; 34(2):71-5. PubMed ID: 8929749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis.
    Teigen MM; Duffull S; Dang L; Johnson DW
    J Clin Pharmacol; 2006 Nov; 46(11):1259-67. PubMed ID: 17050791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dialyzer membrane permeability and survival in hemodialysis patients.
    Chauveau P; Nguyen H; Combe C; Chêne G; Azar R; Cano N; Canaud B; Fouque D; Laville M; Leverve X; Roth H; Aparicio M;
    Am J Kidney Dis; 2005 Mar; 45(3):565-71. PubMed ID: 15754279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
    Nunn MO; Corallo CE; Aubron C; Poole S; Dooley MJ; Cheng AC
    Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen.
    Kamel Mohamed OH; Wahba IM; Watnick S; Earle SB; Bennett WM; Ayres JW; Munar MY
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):694-9. PubMed ID: 17699484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monitoring hemodialysis dose with ionic dialisance in on-line hemodiafiltration].
    Maduell F; Puchades MJ; Navarro V; Torregrosa E; Rius A; Sánchez JJ
    Nefrologia; 2005; 25(5):521-6. PubMed ID: 16392302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis.
    Zelenitsky SA; Ariano RE; McCrae ML; Vercaigne LM
    Clin Infect Dis; 2012 Aug; 55(4):527-33. PubMed ID: 22573855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adequacy in dialysis: intermittent versus continuous therapies.
    Misra M; Nolph KD
    Nefrologia; 2000; 20 Suppl 3():25-32. PubMed ID: 10835874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.